Kornimate/medical-research-clean huggingface dataset:
upper extremity function, shoulder position sense and disability level i̇n patients with multiple sclerosis

Conditions: Physical Therapy; Upper Extremity Function; Position Sense

Summary: the purposes of this study is to investigate the relationship between upper extremity muscle function and shoulder position sense in patients with multiple sclerosis (ms) and which best projects the disability status. upper extremity dysfunction is considered to be the main cause of the loss performance of activities of daily living and this problem was include all motor and somatosensory components of function. any failure in each of these components will likely create an impairment in the normal function. one of the most important components of the somatosensory system is joint position sense, a sub-modality of proprioception. position sense disorders are seen from the early stages of the disease and upper extremity function problems is experienced depending on position sense disorders in patients with ms. expanded disability status scale (edss) is one of the most commonly outcome measures in evaluating the level of disability in ms population. because edss scale emphasis on ambulation, so it is insensitive to upper extremity function. but the ability to use walking aids (e.g., canes, walkers, wheelchairs, etc.) may be affected by the ue impairment so shoulder position sense. when literature is examined, there is no study which examines the relationship between upper extremity muscle function and shoulder position sense in patients with multiple sclerosis and which best projects the disability status. for all these reasons, we think that shoulder position sense is changed both dominant and non-dominant side during flexion and abduction movements in mild-moderate ms patients and that these deficits are correlated with upper extremity function and disability level.

this study was aimed to investigate the relationship between upper extremity muscle function and shoulder position sense in patients with ms and which best projects the disability status. 21 pwms and 20 healthy volunteers with matching ages and genders were included the study. a neurologic examination was performed using the edss by a neurologist. upper extremity function was evaluated with 9-hole peg test (9-hpt). shoulder position sense was evaluated with dualer iqtm digital inclinometer (j-tech medical, salt lake city, uk, usa).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of multiple sclerosis disease * the level of disability should be between 0.5-4 according to edss exclusion criteria: * patients with acute attacks (three months prior to the study) * mini-mental state examination (mmse) score of less tahn 25 points * history of shoulder injury, surgery, medical problems or other neurological disorders in any of the participants

Keywords: multiple sclerosis upper extremity function position sense
reduced atg plus mini ptcy for gvhd prophylaxis in haplo-sct

Conditions: Myelodysplastic Syndrome; Acute Leukemia

Summary: allogeneic hematopoietic stem cell transplantation (allo-hsct) is regarded as a curative therapy for a variety of hematological malignancies and nonmalignant diseases. however, donor limitations have restricted the widespread use of allo-hsct for a long period. the development and success of haploidentical allografts worldwide makes "everyone has a donor" a reality. in the past two decades, researchers have established several haploidentical hsct (haplo-hsct) protocols based on different approaches to induce immune tolerance. the representative approaches for haplo-hsct without in vitro. t cell depletion include granulocyte colony-stimulating factor (g-csf) plus anti-human thymocyte immunoglobulin (atg) based (beijing protocol) and post-transplantation cyclophosphamide based (pt-cy, baltimore protocol) protocols. both of two protocols have common problems that need to be solved, including infection transplantation related mortality and disease relapse. the main aim of this study is to explore whether the combined protocol can improve the efficacy of haploidentical transplantation further.


Eligibility criteria:
inclusion criteria: 1. patients with al - cr and/or myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation for the first time; 2. no gender limit, aged 12 - 65 years; 3. planned haploidentical donor transplantation, excluding transplantation from maternal and collateral donors; 4. eastern cooperative oncology group (ecog) performance status score≤3 points; 5. baseline organ function tests meet the following criteria: (1) left ventricular ejection fraction (lvef) \> 55%; (2) serum creatinine ≤ 1.5 × upper limit of normal (uln). exclusion criteria: 1. patients with severe dysfunction of brain, heart, kidney or liver; 2. those in refractory malignant status; 3. patients with other malignancies requiring treatment; 4. presence of uncontrolled severe active infection clinically; 5. expected survival period of less than 3 months; 6. history of severe allergic reactions; 7. pregnant or breastfeeding women; (8)presence of any condition deemed by the investigator as unsuitable for study enrollment.
first approach for aspirin misuse objective screening

Conditions: Peripheral Arterial Disease

Summary: prospective interventional study. the aim is to analyse the effect of usual ongoing treatments over the microvascular cutaneous response to galvanic current application (current induced vasodilation ; civ) on the forearm of subjects referred for ultrasound investigations due to suspicion of peripheral artery disease. hypothesis is that the use of aspirin (even at low dose) abolishes the response .

at admission eligible patients are proposed to participate. written consent is signed after complete oral and written explanation of the protocol is signed. no register of non-included patients will be kept. in included patients, in parallel to the routine ultrasound investigation for which the patient is referred, microvascular investigation will be performed as explained later in arm description. usual ongoing treatments are obtained by history and recorded. the end of the visit is the end of the participation of the subjects.

Eligibility criteria:
inclusion criteria: * subjects referred for investigation of peripheral arterial disease. * affiliation to the french national healthcare system * french speaking patients * ability to stand still for half a minute. exclusion criteria: * pregnancy * inability to understand the study goal * patients protected by decision of law
comparative study on the effects of epidural dexmedetomidine on heart rate variability during general anesthesia in patients undergoing gastrectomy

Conditions: Gastric Cancer

Summary: the use of epidural dexmedetomidine decreases the anaesthetic requirements and improved postoperative pain. dexmedetomidine is a potent and highly selective a2-adrenoceptor agonist and has sympatholytic effect. power spectral analysis of heart rate variability(hrv) is a useful tool to assess cardiac autonomic activity. we investigated whether preemptive epidural dexmedetomidine can develop hemodynamic change and it could be identify patients by hrv.


Eligibility criteria:
inclusion criteria: * patients consented to spinal anesthesia were enrolled * patients aged 40\~70 years olds undergoing gastrectomy * no contraindication of epidural analgesia * asa class i and ii * patients consented to epidural anesthesia were enrolled exclusion criteria: * patients with hypovolemia, coagulation disorders, local infection at the site of operation, history of headache, heart diseases, and history of allergy, chronic alcohol use or abuse, anemia, congenital heart diseases, bundle block, congestive heart failure or arrythmias * patients who had recently received sedative drugs or were under antidepressant treatment were not included in the study

Keywords: dexmedetomidine heart rate variability preemptive epidural gastrectomy
ipack versus popliteal sciatic nerve block in acl reconstruction

Conditions: Anterior Cruciate Ligament Tear

Summary: this is a prospective study comparing femoral nerve block plus sciatic nerve block to femoral nerve block plus infiltration of the posterior knee capsule (ipack) in patients undergoing arthroscopic anterior cruciate ligament reconstruction. femoral nerve block via the adductor canal (fnb-ac) with ipack may provide effective analgesia while avoiding the motor block involved with sciatic nerve block. the lack of motor block is important to facilitate postoperative ambulation and physical therapy.


Eligibility criteria:
inclusion criteria: * patients less than 21 years of age * american society of anesthesiologists physical status i and ii * undergoing elective anterior cruciate ligament reconstruction exclusion criteria: * they are unable or unwilling to take part in the study * history of allergy to any of the medications administered for the nerve block * contraindication to peripheral nerve block * patients who are unable to understand instructions or questions related to the study or the families required language interpretation * patients who consume opioid medications for more than three days per week for more than a month prior to surgery
probiotics supplementation effect on glucose homeostasis in children with type 1 diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: background: probiotics influence immune homeostasis, through altering gut microbiota. the efficacy of probiotics in diabetes has been shown in preclinical settings as well as in human trials. interleukin (il)-21 and il22 have been implicated in the pathogenesis of t1d. objectives: to assess the effect of oral supplementation with probiotics on glycemic control as well as il-21 and il-22 levels in children with t1d. methods: this randomized-controlled trial study included 70 children with t1d. enrolled children aged 5-18 years with disease duration \> 1 year. they were randomly assigned into two groups; intervention group (group a) who received oral probiotics containing lactobacillus acidophilus la-14 (108 cfu) 0.5 mg once daily. the other group (group b) did not receive any supplementation and served as a control group. both groups were followed-up for 6 months with assessment of fasting blood glucose (fbg), hba1c, il-21 and il-22 levels.


Eligibility criteria:
inclusion criteria: * t1d exclusion criteria: * other types of dm
effects of neck stabilization exercise with heat therapies

Conditions: Neck Pain

Summary: in this study, we aimed to determine the effects of heat therapies and neck stabilization exercises on pain, disability, range of motion, and mood of np patients.

chronic non-specific neck pain (np) has become one of the main causes of disability in the adult population around the world.several treatment options used like; exercise, manual therapy, electrotherapy, and hot treatments etc. in this study, we aimed to determine the effects of heat therapies and neck stabilization exercises on pain, disability, range of motion, and mood of np patients.100 patients with np will be included.patients will be randomyl assigned to 4 groups and will receive a total of 3 weeks of treatment. patients' pain levels (visual analogoue scale vas), quality of life (short form 36), mood (beck deppression inventory bdi), range of motion, and neck disability index were evaluated prior to treatment, at 6th and at 12th weeks.

Eligibility criteria:
inclusion criteria: patients with chronic neck pain exclusion criteria: * sensory deficit on neck area, servical disc pathologies, neurological deficit, malignity, secondary causes for neck pain, active inflammation, arthritis on the neck area, serious mental health problems, pregnancy, spine surgery, and having received treatment to the cervical region in the last 6 months

Keywords: hot pack exercise ultrasound therapy
prebiotic vs probiotic in multiple sclerosis

Conditions: Multiple Sclerosis; Clinically Isolated Syndrome (CIS)

Summary: this is a randomized crossover-designed study to explore the immunologic effects of prebiotics, as opposed to direct supplementation with beneficial bacteria (probiotics) in the immune system of patients with ms and clinically isolated syndrome (cis). eligible patients will take 6 weeks of two different supplements - prebiotics and probiotics. participants will be randomly assigned to take either of two agents for 6 weeks as their first supplement. then, participants enter a 6-week washout period. after the washout period, participants will take the second supplement for 6 weeks. after taking the second supplement, participants will have a 6-week washout period.

soluble fibers (prebiotics) are fermented by beneficial bacteria (probiotics) in the colon to produce short-chain fatty acids (scfas) which are the main source of nutrition for the cells in the gut. it has been reported that the fermentable fiber inulin and scfas may exert some beneficial effects including anti-inflammatory effect on the immune system. to date, the effect of supplementation with fermentable dietary fiber, such as prebiotics in patients with multiple sclerosis (ms) has not been investigated.

Eligibility criteria:
inclusion criteria: * adult patients (age 18 or older) diagnosed with ms (relapsing-remitting type) or cis and recruited within 10 years of symptom onset, and * adult patients receiving anti-cd20 therapy (rituximab or ocrelizumab) who have received at least one cycle at the time of recruitment exclusion criteria: * active relapse within 3 months of enrollment * steroid use within 4 weeks of enrollment * antibiotics use within 3 months of enrollment * daily pre or prebiotic use within 3 months of enrollment * diagnosed with any of the autoimmune disorders: rheumatoid arthritis, lupus, celiac disease, vitiligo, psoriasis, psoriatic arthritis, hashimoto's thyroiditis, graves' disease, sjogren's syndrome, type 1 diabetes, scleroderma, crohn's disease, ulcerative colitis, alopecia areata. * had surgery of the gi tract in the last 5 years (with the exception of cholecystectomy and appendectomy) * had a major bowel resection * prior use of any of the following drugs: mycophenolate/cellcept, cyclophosphamide/cytoxan, methotrexate/novantrone, azathioprine/imuran, cladribine/leustatin/mavenclad, daclizumab/zenepax, alemtuzumab/campath/lemtrada * have any of the following active uncontrolled gastrointestinal (gi) illnesses: 1. crohn's disease, ulcerative colitis, indeterminate colitis 2. irritable bowel syndrome: moderate-severe 3. persistent or chronic diarrhea of unknown etiology 4. severe chronic constipation or difficulties with defecation 5. persistent, infectious gastroenteritis, colitis or gastritis 6. clostridium difficile infection (recurrent) 7. gastric or intestinal ulcerations/gi bleeding 8. gastrointestinal or colonic malignancy: polyps, masses, dysplasia or cancer * active use of bismuth subsalicylate-containing products * currently pregnant

Keywords: prebiotics probiotics gut microbiome multiple sclerosis
glutamate-glutamine cycling (vcyc) during cocaine abstinence using 1h-mrs

Conditions: Cocaine Dependence; Healthy

Summary: this study is designed to look at the relationship between brain glucose utilization, neurotransmission (e.g., glutamate, also known as the main excitatory amino-acid neurotransmitter in the brain), and synaptic density. this relationship will be explored in the brain's prefrontal cortex, an area important in decision-making and impulsivity.


Eligibility criteria:
inclusion criteria: 1. age 18-55 years; 2. voluntary, written, informed consent; 3. physically healthy by medical history, physical, neurological, ecg and laboratory examinations; 4. dsm-iv criteria for cocaine dependence (304.20) (note: subjects will also meet dsm-5 criteria for cocaine use disorder); 5. documented evidence (by urine toxicology) of abstinence from cocaine (2 weeks for scan 1, and 2 and 4 weeks for scans 2 and 3, respectively) 6. full scale and verbal iqs \> 80; 7. for females, a negative serum pregnancy test (β-hcg) at screening and negative urine pregnancy test on pet scan day prior to imaging. exclusion criteria: 1. a history of other substance dependence (e.g., alcohol, opiates, sedative hypnotics), except for nicotine; 2. a primary dsm-iv axis i major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the structured clinical interview for dsm-iv (scid); 3. a history of significant medical (e.g., cardiovascular, diabetic/metabolic) or neurological (e.g., cerebrovascular, seizure, traumatic brain injury) illness; 4. current use of psychotropic and/or potentially psychoactive prescription medications; 5. medical contraindications to participation in a magnetic resonance imaging procedure (e.g., ferromagnetic implants/foreign bodies, claustrophobia, cardiac pacemaker, prosthetic valve, otologic implant, etc.); 6. for females, laboratory (β-hcg) evidence of pregnancy, physical evidence of pregnancy; 7. for subjects interested in pharmacotherapy component, history of allergies to nac and current elevation on liver function tests above twice the normal limit; 8. subjects with history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over fda limits for annual radiation exposure. this guideline is an effective dose of 5 rem received per year; 9. subjects with current, past or anticipated exposure to radiation in the work place within one year of proposed research pet scans; 10. history of a bleeding disorder or are currently taking anticoagulants (such as coumadin, heparin, pradaxa, xarelto); 11. blood donation within eight weeks of the start of the study.
safety/tolerability study of alcohol injection for treatment of bph (enlarged prostate)

Conditions: Prostate Disease; BPH; Benign Prostatic Hyperplasia; Benign Prostatic Hypertrophy

Summary: multi-center, prospective randomized dosing and safety research study. a maximum of 150 men will be enrolled in the study. qualifying patients will receive one of three possible doses of the study drug. symptoms will be evaluated before treatment, and then 1-week, 1-month, 3-months, and 6-months following treatment.


Eligibility criteria:
eligible patients are 50 to 80-year-old men who have experienced some or all of the following urinary symptoms for at least 6 months: * frequent or urgent need to urinate * difficulty starting their urinary stream * interruption of their urinary stream * feeling of incomplete emptying of bladder after urinating * interruption of sleep due to the urge to urinate patients should have tried oral medication for their condition in the past, and be willing to discontinue any current bph medications for a period of time before undergoing study treatment. they should be in good general health and have no previous surgery, or other procedure(s) intended to reduce prostate size.

Keywords: prostate bph prostatitis
analysis of headache chronification with imaging, deep phenotyping, and proteomics

Conditions: Chronic Daily Headache; Chronic Migraine

Summary: study is aimed at determining why some patients with episodic headache proceed to chronic daily or near daily headaches. the investigators seek to discover differences in brain anatomy and function, composition of cerebrospinal fluid, blood products, genetics, and patient phenotypes that might help explain this process.

the purpose of our study is to better understand disease processes and risk factors involved in onset of chronic daily headaches/chronic migraines. further, the investigators hopes to learn more about the etiology and disease mechanisms to optimize treatment strategies and determine prophylactic measures. participation in this research study, will include online questionnaires, a blood sample, a lumbar puncture, and a magnetic resonance imaging (mri) scan without contrast to measure brain activity. participant may select to participate in a magnetic resonance imaging (mri) scan and/ or lumbar puncture. participating in atleast 3 procedures is required (blood draw, online questionnaires , mri and/or spinal tap. the study recruits participants with headache ( any type of headaches), and patients with no headaches ( or less than 2/year). participants do not need to have a specified headache type. all participants are asked to complete an on-line survey to characterize a number of phenotypic features felt to be relevant by the investigators. three independent study groups (imaging, proteomics/genetics, and phenotyping) analyze data independently and stratify the data. then, by group analysis, correlation among the different modalities is sought to identify features that distinguish common elements that might help elucidate features that could predict which patients with episodic headache are likely to progress to chronic, and which patients without headache might be at greater risk to develop new daily persistent headache.

Eligibility criteria:
inclusion criteria: * subjects must agree to sign informed consent. * subject must be able to or at least with some help willing to complete online questionnaires in english . * willing to comply with study instructions. * must speak and understand english exclusion criteria: \*any neurological condition, at the discretion of the principal investigator (pi)

Keywords: headaches tension-type headache new daily persistent headache (ndph) migraine
a clinical trial to investigate the efficacy and safety of evogliptin

Conditions: Type 2 Diabetes Mellitus

Summary: this is a randomized, double-blind, placebo-controlled, phase iii clinical trial to investigate the efficacy and safety of evogliptin after oral administration in patients with type 2 diabetes who have inadequate glycemic control on diet and exercise.

1. evogliptin 5mg group: administration with evogliptin 5mg for 0-52 weeks. 2. placebo group: administration with placebo for 0-24 weeks, and with evogliptin 5mg for 24-52 weeks.

Eligibility criteria:
inclusion criteria: * subjects with 6.5%≤hba1c≤10.0% at screening * subjects untreated with oral hypoglycemic agents within 6 weeks prior to screening * subjects with 6.5%≤hba1c≤10.0% at visit 2 * subjects with 20kg/m2≤bmi≤40kg/m2 at screening exclusion criteria: * subjects with fasting plasma glucose≥270mg/dl at screening * patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus * subjects with history of myocardial infarction, cerebral infarction within 6 months prior to screening * subjects with alt and ast 2.5 times or higher than upper normal range

Keywords: da-1229 evogliptin dpp-iv inhibitor suganon dpp-4 inhibitor